Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TCD With Transfusions Changing to Hydroxyurea (TWiTCH): A Phase III Randomized Clinical Trial to Compare Standard Therapy (Erythrocyte Transfusions) With Alternative Therapy (Hydroxyurea) for the Maintenance of Lowered TCD Velocities in Pediatric Subjects With Sickle Cell Anemia and Abnormal Pre-treatment TCD Velocities

Next Previous
Trial Profile

TCD With Transfusions Changing to Hydroxyurea (TWiTCH): A Phase III Randomized Clinical Trial to Compare Standard Therapy (Erythrocyte Transfusions) With Alternative Therapy (Hydroxyurea) for the Maintenance of Lowered TCD Velocities in Pediatric Subjects With Sickle Cell Anemia and Abnormal Pre-treatment TCD Velocities

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 06 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Hydroxycarbamide (Primary)
  • Indications Sickle cell anaemia
  • Focus Therapeutic Use
  • Acronyms TWiTCH

Most Recent Events

  • 06 Dec 2016 Results of iron burden in the different organs (n=120) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
  • 06 Dec 2016 Results analysing agreement between measurements of dLIC over a period of one year by MRI R2 (FerriScan) and R2* methods, presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
  • 06 Dec 2016 Primary endpoint has been met. (TCD Mean Velocity at 24 months on the index side) as per rsults presented at the 58th Annual Meeting and Exposition of the American Society of Hematology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top